<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03206918</url>
  </required_header>
  <id_info>
    <org_study_id>BGB-3111-205</org_study_id>
    <secondary_id>CTR20160890</secondary_id>
    <nct_id>NCT03206918</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</brief_title>
  <official_title>A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate Safety and Efficacy of BGB-3111, a Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>BeiGene</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>BeiGene</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a single-arm, open-label, multi-center Phase 2 study in participants with&#xD;
      histologically documented CLL/SLL who have relapsed after or refractory to ≥ 1 prior&#xD;
      treatment regimen(s). The study is composed of an initial screening phase, a single-arm&#xD;
      treatment phase, and a follow-up phase.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 9, 2017</start_date>
  <completion_date type="Actual">September 10, 2020</completion_date>
  <primary_completion_date type="Actual">June 15, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR) by Independent Review Committee (IRC)</measure>
    <time_frame>Up to 1 year and 4 months</time_frame>
    <description>ORR is defined as the number of participants who achieve a best response of CR or, CRi, Nodular Partial Response, PR, and PR with Lymphocytosis as assessed by IRC per the modified IWCLL Guidelines in participants with CLL and the Revised Criteria for Response for Malignant Lymphoma in participants with SLL.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival (PFS): Percentage of Participants Progression/Death Event Free</measure>
    <time_frame>6, 12, 24, and 36 months</time_frame>
    <description>PFS is defined as the time from treatment initiation to first documentation of progression by International workshop on chronic lymphocytic leukemia (IWCLL) criteria/revised criteria for response for malignant lymphoma or death, whichever is earlier.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR): Event Free Rate - Percentage of Participants Who Remained Event Free</measure>
    <time_frame>6, 12, 24, and 36 months</time_frame>
    <description>DOR is defined as the time from the date that response criteria are first met to the date that progressive disease (PD) is objectively documented or death, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response (TTR)</measure>
    <time_frame>Up to 3.5 years</time_frame>
    <description>TTR is defined as the time from treatment initiation to first signs of response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate as Determined by the Investigator</measure>
    <time_frame>up to 3.5 years</time_frame>
    <description>Overall response was defined as achieving a best overall response of CR, CRi, nodular partial response (nPR), PR, or partial response with lymphocytosis (PR-L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Adverse Events (AEs)</measure>
    <time_frame>Up to 3.5 years</time_frame>
    <description>An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. All AEs were monitored per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE version [v] 4.03 2010). A treatment emergent adverse event (TEAE) is defined as an adverse event that has an onset date or a worsening in severity from baseline (pretreatment) on or after the date of first dose of study drug up to 30 days following study drug discontinuation or initiation of new anticancer therapy, whichever occurs first.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">91</enrollment>
  <condition>Relapsed or Refractory Chronic Lymphocytic Leukemia</condition>
  <condition>Relapsed or Refractory Small Lymphocytic Lymphoma</condition>
  <arm_group>
    <arm_group_label>Zanubrutinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zanubrutinib</intervention_name>
    <description>Zanubrutinib 160 mg (two - 80 mg white opaque capsules) taken by mouth (PO) twice a day (BID)</description>
    <arm_group_label>Zanubrutinib</arm_group_label>
    <other_name>BGB-3111</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis with at least one criterion for treatment according to&#xD;
             International workshop on chronic lymphocytic leukemia (IWCLL)&#xD;
&#xD;
          2. Eastern Cooperative Oncology Group (ECOG) performance status of 0-2&#xD;
&#xD;
          3. Measurable disease by contrast enhanced computerized tomography / magnetic resonance&#xD;
             imaging (CT/MRI).&#xD;
&#xD;
          4. Previously treated with a minimum of 1 prior line of standard chemotherapy-containing&#xD;
             regimen (with completion of ≥2 treatment cycles).&#xD;
&#xD;
          5. Documented failure to achieve at least partial response (PR) or documented disease&#xD;
             progression after response to the most recent treatment regimen. Refractory disease is&#xD;
             defined as treatment failure (stable disease, non-response, progressive disease [PD])&#xD;
             or disease progression within 6 months after the most recent prior therapy (Hallek et&#xD;
             al, 2008).&#xD;
&#xD;
          6. Neutrophils ≥ 0.75 x 109/L independent of growth factor support within 7 days of study&#xD;
             entry&#xD;
&#xD;
          7. Platelets ≥ 50 x 109/L, independent of growth factor support or transfusion within 7&#xD;
             days of study entry&#xD;
&#xD;
          8. Creatinine clearance of ≥ 30 ml/min (as estimated by the Cockcroft-Gault equation or&#xD;
             estimated glomerular filtration rate [eGFR] from the Modification of Diet in Renal&#xD;
             Disease [MDRD])&#xD;
&#xD;
          9. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 x ULN&#xD;
&#xD;
         10. Bilirubin ≤2 x ULN (unless documented Gilbert's syndrome)&#xD;
&#xD;
         11. International normalized ratio (INR) ≤1.5 and activated partial thromboplastin time&#xD;
             (APTT) ≤1.5 x ULN.&#xD;
&#xD;
         12. Participants may be enrolled who relapse after autologous stem cell transplant if they&#xD;
             are at least 6 months after transplant.&#xD;
&#xD;
         13. Life expectancy of &gt;4 months&#xD;
&#xD;
         14. Echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) ≥50%;&#xD;
             (AHA, 2016)&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Current or history of central nervous system (CNS) lymphoma&#xD;
&#xD;
          2. Prior exposure to a Bruton's tyrosine kinase (BTK) inhibitor&#xD;
&#xD;
          3. Prior corticosteroids given in excess of prednisone 10 mg/day or its equivalent with&#xD;
             antineoplastic intent within 7 days.&#xD;
&#xD;
          4. Major surgery within 4 weeks of screening&#xD;
&#xD;
          5. Not recovered from toxicity of any prior anti-cancer therapy to &lt;Grade 1 (except for&#xD;
             alopecia, absolute neutrophil count (ANC) and platelets.&#xD;
&#xD;
          6. History of other active malignancies within 2 years of study entry, with exception of&#xD;
             (1) adequately treated in-situ carcinoma of cervix; (2) localized basal cell or&#xD;
             squamous cell carcinoma of skin; (3) previous malignancy confined and treated locally&#xD;
             (surgery or other modality) with curative intent&#xD;
&#xD;
          7. Currently active clinically significant cardiovascular disease&#xD;
&#xD;
          8. QTcF &gt;480 msecs based on Fridericia's formula or other significant electrocardiogram&#xD;
             abnormalities including second degree atrioventricular (AV) block Type II, or third&#xD;
             degree AV block&#xD;
&#xD;
          9. Unable to swallow capsules or disease significantly affecting gastrointestinal&#xD;
             function such as malabsorption syndrome, resection of the stomach or small bowel,&#xD;
             symptomatic inflammatory bowel disease, or partial or complete bowel obstruction&#xD;
&#xD;
         10. Active infection including infections requiring oral or intravenous anti-microbials&#xD;
&#xD;
         11. Known human immunodeficiency virus (HIV), or active hepatitis B or hepatitis C&#xD;
             infection (detected positive by polymerase chain reaction [PCR]).&#xD;
&#xD;
         12. Has received allogenic hematopoietic stem cell transplantation prior to enrollment&#xD;
&#xD;
         13. Any life-threatening illness, medical condition or organ system dysfunction which, in&#xD;
             the investigator's opinion, could compromise the participants's safety, or put the&#xD;
             study at risk&#xD;
&#xD;
         14. Requires ongoing treatment with any medication which is a strong cytochrome P450,&#xD;
             family 3, subfamily A (CYP3A) inhibitor or strong CYP3A inducer&#xD;
&#xD;
         15. Known or clinically suspected Richter's transformation at the time of study entry&#xD;
&#xD;
         16. History of stroke or intracranial hemorrhage within 6 months prior to enrollment&#xD;
&#xD;
        NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Principal Investigator</role>
    <affiliation>BeiGene</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100082</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University Union Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350001</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanfang Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Guangxi Medical University</name>
      <address>
        <city>Nanning</city>
        <state>Guangxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Guangdong Provincial People's Hospital</name>
      <address>
        <city>Guangdong</city>
        <state>Guangzhou</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henan Cancer Hospital</name>
      <address>
        <city>Zhengzhou</city>
        <state>Henan</state>
        <zip>450008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital of Tongji Medical College of HUST</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jiangsu Province Hospital</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210029</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affilliated Hospital of Jinlin University</name>
      <address>
        <city>Changchun</city>
        <state>Jinlin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruijin Hospital Shanghai Jiaotong University School of Medicine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Xi 'an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West China Hospital of Sichuan University</name>
      <address>
        <city>Chengdu</city>
        <state>Sichuan</state>
        <zip>610041</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Hematonosis Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300020</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Xu W, Yang S, Zhou K, Pan L, Li Z, Zhou J, Gao S, Zhou D, Hu J, Feng R, Huang H, Ji M, Guo H, Huang J, Novotny W, Feng S, Li J. Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. J Hematol Oncol. 2020 May 11;13(1):48. doi: 10.1186/s13045-020-00884-4.</citation>
    <PMID>32393328</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 29, 2017</study_first_submitted>
  <study_first_submitted_qc>June 29, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 2, 2017</study_first_posted>
  <results_first_submitted>August 10, 2020</results_first_submitted>
  <results_first_submitted_qc>September 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 25, 2020</results_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Bruton's tyrosine kinase</keyword>
  <keyword>Chronic lymphocytic leukemia</keyword>
  <keyword>Relapsed/refractory</keyword>
  <keyword>Zanubrutinib</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zanubrutinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 25, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT03206918/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 16, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/18/NCT03206918/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>91 participants were enrolled at 11 sites in China. The first participant was dosed on 09 March 2017. Database lock date for the primary outcome measure was 14 December 2018. Final database lock date was 16 October 2020.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Zanubrutinib</title>
          <description>160 mg administered orally (two - 80 mg white opaque capsules) twice a day (BID) for up to three years or until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by the sponsor.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transferred to extension study BGB-3111-LTE1 (NCT04170283)</title>
              <participants_list>
                <participants group_id="P1" count="60"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set: All participants who received any dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Zanubrutinib</title>
          <description>160 mg administered orally (two - 80 mg white opaque capsules) twice a day (BID) for up to three years or until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by the sponsor.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="91"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.9" spread="9.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>&lt;65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>≥65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Chinese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate (ORR) by Independent Review Committee (IRC)</title>
        <description>ORR is defined as the number of participants who achieve a best response of CR or, CRi, Nodular Partial Response, PR, and PR with Lymphocytosis as assessed by IRC per the modified IWCLL Guidelines in participants with CLL and the Revised Criteria for Response for Malignant Lymphoma in participants with SLL.</description>
        <time_frame>Up to 1 year and 4 months</time_frame>
        <population>Modified Safety Analysis Set: All participants in the safety analysis set who had confirmed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)</population>
        <group_list>
          <group group_id="O1">
            <title>Zanubrutinib</title>
            <description>160 mg administered orally (two - 80 mg white opaque capsules) twice a day (BID) for up to 3.5 years or until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by the sponsor.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR) by Independent Review Committee (IRC)</title>
          <description>ORR is defined as the number of participants who achieve a best response of CR or, CRi, Nodular Partial Response, PR, and PR with Lymphocytosis as assessed by IRC per the modified IWCLL Guidelines in participants with CLL and the Revised Criteria for Response for Malignant Lymphoma in participants with SLL.</description>
          <population>Modified Safety Analysis Set: All participants in the safety analysis set who had confirmed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Exact Binomial Test</method>
            <method_desc>The null hypothesis is ORR = 32%</method_desc>
            <param_type>2-side Clopper-Pearson</param_type>
            <param_value>87.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>79.40</ci_lower_limit>
            <ci_upper_limit>93.81</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival (PFS): Percentage of Participants Progression/Death Event Free</title>
        <description>PFS is defined as the time from treatment initiation to first documentation of progression by International workshop on chronic lymphocytic leukemia (IWCLL) criteria/revised criteria for response for malignant lymphoma or death, whichever is earlier.</description>
        <time_frame>6, 12, 24, and 36 months</time_frame>
        <population>The Safety Analysis Set included all participants who received ≥ 1 doses of study drug. All efficacy analyses were based on the Safety Analysis Set</population>
        <group_list>
          <group group_id="O1">
            <title>Zanubrutinib</title>
            <description>160 mg administered orally (two - 80 mg white opaque capsules) twice a day (BID) for up to 3.5 years or until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by the sponsor.</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS): Percentage of Participants Progression/Death Event Free</title>
          <description>PFS is defined as the time from treatment initiation to first documentation of progression by International workshop on chronic lymphocytic leukemia (IWCLL) criteria/revised criteria for response for malignant lymphoma or death, whichever is earlier.</description>
          <population>The Safety Analysis Set included all participants who received ≥ 1 doses of study drug. All efficacy analyses were based on the Safety Analysis Set</population>
          <units>Percentage of participants</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3" lower_limit="85.72" upper_limit="96.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88.7" lower_limit="80.04" upper_limit="93.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.5" lower_limit="70.52" upper_limit="87.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.1" lower_limit="56.56" upper_limit="77.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response (DOR): Event Free Rate - Percentage of Participants Who Remained Event Free</title>
        <description>DOR is defined as the time from the date that response criteria are first met to the date that progressive disease (PD) is objectively documented or death, whichever occurs first</description>
        <time_frame>6, 12, 24, and 36 months</time_frame>
        <population>The Safety Analysis Set included all participants who received ≥ 1 doses of study drug. Duration of response was summarized for responders (with Best Overall Response of partial response with lymphocytosis (PR-L) or above) only</population>
        <group_list>
          <group group_id="O1">
            <title>Zanubrutinib</title>
            <description>160 mg administered orally (two - 80 mg white opaque capsules) twice a day (BID) for up to 3.5 years or until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by the sponsor.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response (DOR): Event Free Rate - Percentage of Participants Who Remained Event Free</title>
          <description>DOR is defined as the time from the date that response criteria are first met to the date that progressive disease (PD) is objectively documented or death, whichever occurs first</description>
          <population>The Safety Analysis Set included all participants who received ≥ 1 doses of study drug. Duration of response was summarized for responders (with Best Overall Response of partial response with lymphocytosis (PR-L) or above) only</population>
          <units>Percentage of participants</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>6 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.5" lower_limit="90.37" upper_limit="99.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.5" lower_limit="83.96" upper_limit="96.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>24 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.4" lower_limit="73.20" upper_limit="90.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>36 Months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.9" lower_limit="57.02" upper_limit="79.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Response (TTR)</title>
        <description>TTR is defined as the time from treatment initiation to first signs of response</description>
        <time_frame>Up to 3.5 years</time_frame>
        <population>The Safety Analysis Set included all participants who received ≥ 1 doses of study drug. Time to response was summarized for responders (those who achieved a best overall response of at least PR-L) only</population>
        <group_list>
          <group group_id="O1">
            <title>Zanubrutinib</title>
            <description>160 mg administered orally (two - 80 mg white opaque capsules) twice a day (BID) for up to 3.5 years or until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by the sponsor.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Response (TTR)</title>
          <description>TTR is defined as the time from treatment initiation to first signs of response</description>
          <population>The Safety Analysis Set included all participants who received ≥ 1 doses of study drug. Time to response was summarized for responders (those who achieved a best overall response of at least PR-L) only</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="80"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.79" lower_limit="2.6" upper_limit="16.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Response Rate as Determined by the Investigator</title>
        <description>Overall response was defined as achieving a best overall response of CR, CRi, nodular partial response (nPR), PR, or partial response with lymphocytosis (PR-L).</description>
        <time_frame>up to 3.5 years</time_frame>
        <population>The Safety Analysis Set included all participants who received ≥ 1 doses of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Zanubrutinib</title>
            <description>160 mg administered orally (two - 80 mg white opaque capsules) twice a day (BID) for up to 3.5 years or until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by the sponsor.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate as Determined by the Investigator</title>
          <description>Overall response was defined as achieving a best overall response of CR, CRi, nodular partial response (nPR), PR, or partial response with lymphocytosis (PR-L).</description>
          <population>The Safety Analysis Set included all participants who received ≥ 1 doses of study drug.</population>
          <units>Percentage of participants</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.3" lower_limit="84.79" upper_limit="96.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Experiencing Adverse Events (AEs)</title>
        <description>An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. All AEs were monitored per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE version [v] 4.03 2010). A treatment emergent adverse event (TEAE) is defined as an adverse event that has an onset date or a worsening in severity from baseline (pretreatment) on or after the date of first dose of study drug up to 30 days following study drug discontinuation or initiation of new anticancer therapy, whichever occurs first.</description>
        <time_frame>Up to 3.5 years</time_frame>
        <population>The Safety Analysis Set included all participants who received ≥ 1 doses of study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Zanubrutinib</title>
            <description>160 mg administered orally (two - 80 mg white opaque capsules) twice a day (BID) for up to3.5 years or until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by the sponsor.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Adverse Events (AEs)</title>
          <description>An adverse event (AE) was defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. All AEs were monitored per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE version [v] 4.03 2010). A treatment emergent adverse event (TEAE) is defined as an adverse event that has an onset date or a worsening in severity from baseline (pretreatment) on or after the date of first dose of study drug up to 30 days following study drug discontinuation or initiation of new anticancer therapy, whichever occurs first.</description>
          <population>The Safety Analysis Set included all participants who received ≥ 1 doses of study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="91"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At Least 1 TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Grade 3 or higher TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to treatment discontinuation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to treatment modification</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to treatment interruption</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to dose reduction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Treatment-related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 3.5 years</time_frame>
      <desc>Safety Analysis Set</desc>
      <group_list>
        <group group_id="E1">
          <title>Zanubrutinib</title>
          <description>160 mg administered orally (two - 80 mg white opaque capsules) twice a day (BID) for up to three years</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Cardiopulmonary failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (23.0)">Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (20.0)">Intestinal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Dermatitis infected</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Hepatitis B</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Splenic infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Cryptococcosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Enteritis infectious</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Brain herniation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (20.0)">Periprosthetic fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (23.0)">Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Osteoarthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (20.0)">Adenocarcinoma gastric</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Cerebrovascular insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (23.0)">Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (23.0)">Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="91" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (23.0)">Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Periodontal disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Nausea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (23.0)">Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (20.0)">Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (20.0)">Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (20.0)">Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (20.0)">Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (20.0)">Periodontitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (20.0)">Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (20.0)">Asymptomatic bacteriuria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (20.0)">Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Hepatitis B reactivation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (20.0)">Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Bacterial test positive</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Blood fibrinogen decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Blood urine present</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Carbon dioxide increased</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Neutrophil percentage decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Red blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Urobilinogen urine increased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (20.0)">Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (20.0)">Low density lipoprotein decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (20.0)">Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (20.0)">Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (20.0)">Bacterial test positive</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (20.0)">Hepatitis B core antibody positive</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">High density lipoprotein decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (20.0)">Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (20.0)">Globulins decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">High density lipoprotein increased</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (20.0)">White blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Blood immunoglobulin A decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Carbon dioxide decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Urine leukocyte esterase positive</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (20.0)">White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (20.0)">Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (20.0)">Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (23.0)">Back pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Headache</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (23.0)">Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Nasal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Haemorrhage subcutaneous</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
              </event>
              <event>
                <sub_title vocab="MedDRA (23.0)">Skin haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="91"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>BeiGene has 18 months from the end of the study at all sites to publish overall study results. After the 1st multi-site publication or the expiration of publication period, Investigators are free to publish/present the results of the study. Investigators must submit all draft publications/presentations to us for review 60 days prior to the planned publication/presentation date. BeiGene may request deletion of its confidential information &amp; may request a further delay to protect its IP rights.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>BeiGene</organization>
      <phone>+1-877-828-5568</phone>
      <email>clinicaltrials@beigene.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

